A Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Trial Investigating the Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Women Aged 35-42 Years Undergoing Assisted Reproductive Technology
Phase of Trial: Phase III
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Follitropin delta (Primary)
- Indications Female infertility
- Focus Registrational; Therapeutic Use
- Acronyms RITA-2
- Sponsors Ferring Pharmaceuticals
- 28 Jan 2019 Planned End Date changed from 31 Dec 2021 to 1 Jun 2020.
- 28 Jan 2019 Planned primary completion date changed from 30 Jun 2020 to 1 Jun 2020.
- 19 Nov 2018 New trial record